Trial Size Available
Carrier-Free Available
| Document Name | |
|---|---|
| Datasheet | Download Here |
| Material Safety Data Sheet | Download Here |
| Applications | Tested Dilutions | Protocol | Note |
|---|---|---|---|
| Immunohistochemistry (IHC) | 1:50-1:100 | IHC Protocol | Manual Protocol: Freshly cut sections should be used (less than 10 days between cutting and staining). Heat-induced antigen retrieval for 5 minutes in an autoclave at 121°C in pH 7.8 Target Retrieval Solution buffer. Apply the antibody at a dilution of 1:50 at 37°C for 60 minutes. Visualization of bound antibody by the EnVision Kit (Dako, Agilent) according to the manufacturer’s directions. |
Progesterone is one of the central regulators of female reproduction. In breast development, progesterone is involved in the formation of lobular-alveolar structures and also affects differentiation in the breast by modulation of milk protein synthesis. The cellular effects of progesterone are mediated through progesterone receptors (PR). PR, a protein with 946 amino acids, is a ligand-activated transcription factor member of the steroid receptor super family of nuclear receptors. PR is predominantly expressed in female sex steroid responsive tissues such as the mammary gland, uterus and ovary but is also found in other tissues such as endocrine cells of the Langerhans' islets. The estrogen receptor (ER) and PR status has been used for over 20 years as a predictor of breast carcinoma responsiveness to endocrine therapy and as a prognostic indicator for early recurrence.
Should a NeoBiotechnologies antibody not meet the experimental expectations outlined on our website or datasheet, please contact our Technical Support. We unconditionally guarantee our product.
Our team of scientists are ready to help you with expert recommendations or technical assistance related to applications or product use.
Information
© 2026 NeoBiotechnologies. All Rights Reserved.
Monday-Friday: 8:00am – 8:00pm Pacific Time